Biktarvy Safety Profile & Adverse Events

Safety Profile Overview

Single-tablet HIV regimen and the most prescribed antiretroviral globally. High barrier to resistance with well-characterized safety profile.

Generic Name

bictegravir/emtricitabine/TAF

Brand Names

Biktarvy

Therapeutic Class

INSTI-Based HIV Regimen

Manufacturer

Gilead

What Pharma Signal Tracks for Biktarvy

Adverse Events (FAERS) — All FDA Adverse Event Reporting System reports mentioning Biktarvy, including serious outcomes, hospitalizations, and deaths.
FDA Recalls — Class I, II, and III recalls, market withdrawals, and safety alerts related to Biktarvy products.
Label Changes — Boxed warning additions, new contraindications, dosing modifications, and safety-related labeling supplements.
Risk Score — Composite risk score (0–100) combining adverse event rates, recall history, and label severity with explainable breakdown.
Pharmacovigilance Signals — Proportional Reporting Ratio (PRR) and Reporting Odds Ratio (ROR) analysis detecting disproportionate adverse reactions.
Trend Analysis — Monthly time series with anomaly detection for emerging safety signals.

Data Disclaimer: Pharma Signal aggregates data from the FDA Adverse Event Reporting System (FAERS) and other public regulatory sources. FAERS reports do not establish causation. Report counts may reflect prescription volume rather than relative safety. Always consult healthcare professionals for medical decisions.

Get Biktarvy Safety Data via API

One API call returns adverse events, risk scores, recalls, and pharmacovigilance signals for Biktarvy.

curl "https://api.pharma-signal.com/drug/safety/biktarvy" \
  -H "X-API-Key: your_key"

# Returns risk score, adverse event counts,
# serious/death rates, recalls, and signals

Try the API API Reference

Related Safety Intelligence

Pharma Signal provides comparative analysis across therapeutic classes. Compare Biktarvy against other INSTI-Based HIV Regimen drugs, or explore the full manufacturer portfolio for Gilead.

Head-to-head comparison — Compare up to 5 drugs side by side on all safety metrics.
Therapeutic class benchmarking — See how Biktarvy ranks within INSTI-Based HIV Regimen on serious event rates.
Company portfolio risk — View all drugs from Gilead with aggregate risk exposure.
AI analyst briefs — Get a natural-language safety assessment combining all data sources.